Title: Research and experiments of a new premedication for improving mucosal visibility during
esophagogastroduodenoscopy
Version: 2 Date: 26 Feb 2025
Reviewer's report:
The authors have evaluated the role of Proteolytic enzyme (FA-1) and two food defoamers
(FA-2 and FA-3) in lowering protein concentration, which is of clinical significance in
Esophagogastroduodenoscopy. However, some revisions should be made before this manuscript
could be published.
Major revisions:
1.The specific disease should be provided. Healthy people, gastric cancer or some else?
2.Protein concentration for gastric juice harvested from each patient should be provided.
3.The protein concentration in foaming model in vitro should be determined by referring to the
protein concentration in gastric juice.
4.In vivo assay to evaluate the visibility should be added, either in patients or in animal model
is acceptable.
5.Different doses of FA-1 should be considered under condition of 37# in gastric juice and in
vitro foaming model
Minor revision:
1.What is the relationship between gastric cancer and FA-1? It is better that the authors minimize
the description of gastric cancer in Introduction part.
2.The authors should discuss the visibility more in detail.
3.The exact component of FA-1,-2,-3 should be provided.
Title: Research and experiments of a new premedication for improving mucosal visibility during
esophagogastroduodenoscopy
Version: 2 Date: 26 Feb 2025
Reviewer's report:
The authors have evaluated the role of Proteolytic enzyme (FA-1) and two food defoamers
(FA-2 and FA-3) in lowering protein concentration, which is of clinical significance in
Esophagogastroduodenoscopy. However, some revisions should be made before this manuscript
could be published.
Major revisions:
1.The specific disease should be provided. Healthy people, gastric cancer or some else?
2.Protein concentration for gastric juice harvested from each patient should be provided.
3.The protein concentration in foaming model in vitro should be determined by referring to the
protein concentration in gastric juice.
4.In vivo assay to evaluate the visibility should be added, either in patients or in animal model
is acceptable.
5.Different doses of FA-1 should be considered under condition of 37# in gastric juice and in
vitro foaming model
Minor revision:
1.What is the relationship between gastric cancer and FA-1? It is better that the authors minimize
the description of gastric cancer in Introduction part.
2.The authors should discuss the visibility more in detail.
3.The exact component of FA-1,-2,-3 should be provided.
Please review this paper.
user
Title: Research and experiments of a new premedication for improving mucosal visibility during
esophagogastroduodenoscopy
Version: 2 Date: 26 Feb 2025
Reviewer's report:
The authors have evaluated the role of Proteolytic enzyme (FA-1) and two food defoamers
(FA-2 and FA-3) in lowering protein concentration, which is of clinical significance in
Esophagogastroduodenoscopy. However, some revisions should be made before this manuscript
could be published.
Major revisions:
1.The specific disease should be provided. Healthy people, gastric cancer or some else?
2.Protein concentration for gastric juice harvested from each patient should be provided.
3.The protein concentration in foaming model in vitro should be determined by referring to the
protein concentration in gastric juice.
4.In vivo assay to evaluate the visibility should be added, either in patients or in animal model
is acceptable.
5.Different doses of FA-1 should be considered under condition of 37# in gastric juice and in
vitro foaming model
Minor revision:
1.What is the relationship between gastric cancer and FA-1? It is better that the authors minimize
the description of gastric cancer in Introduction part.
2.The authors should discuss the visibility more in detail.
3.The exact component of FA-1,-2,-3 should be provided.
assistant